Advertisement

Der Internist pp 338-344 | Cite as

Auslösung und Verstärkung von Herzrhythmusstörungen durch Antiarrhythmika

  • S. H. Hohnloser
  • T. Meinertz
  • M. Zehender
  • A. Geibel
  • H. Just
Chapter

Zusammenfassung

Rhythmusstörungen in Zusammenhang mit klinisch gebräuchlichen Antiarrhythmika können, wie aus der Übersicht hervorgeht, auftreten in Form von Bradyarrhythmien, supraventrikulären Tachyarrhythmien, ventrikulären Tachykardien mit und ohne QT-Verlängerung, ferner als Zunahme vorbestehender ventrikulärer oder elektrisch ausgelöster Arrhythmien. Weiterer Gegenstand der Darstellung sind begünstigende Faktoren und Häufigkeit proarrhythmischer Effekte sowie zugrunde liegende elektrophysiologische Mechanismen.

Schlüsselwörter

Herzrhythmusstörungen Antiarrhythmika Proarrhythmischer Effekt 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. 1.
    Anastasiou-Nana MI, Anderson JL, Stewart JR, Crevey BJ, Yanowitz FG, Lutz JR, Johnson TA (1987) Accurrence of exercise-induced and spontaneous wide complex tachykardia during therapy with flecainide for complex ventricular arrhythmias: A probable proarrhythmic effect. Am Heart J 113:1071–1077PubMedCrossRefGoogle Scholar
  2. 2.
    Andresen D, Leitner ER v, Wegschei-der K, Schröder R (1982) Nachweis komplexer tachykarder ventrikulärer Rhythmusstörungen im Langzeit-EKG: Abhängigkeit von der Registrierdauer. Dtsch Med Wochenschr 107:571–574PubMedCrossRefGoogle Scholar
  3. 3.
    Antoni H (1979) What is measured by the so-called threshold for fibrillation? Progr Pharmacol 2/4:5–12Google Scholar
  4. 4.
    Banai S, Tzivoni D, Schuger C, Benhorin J, Klein J, Chenzbraun A, Gottlieb S, Keren A, Stern S (1987) Effectiveness of magnesium sulfate in torsade de pointes: a study of 9 patients. JACC 9:245AGoogle Scholar
  5. 5.
    Bigger JT Jr (1983) Definition of benign versus malignant ventricular arrhythmias. Targets for treatment. Am J Cardiol 52:47C-54CCrossRefGoogle Scholar
  6. 6.
    Bigger T, Reiffei JA (1979) Sick sinus syndrome. Annu Rev Med 30:91–118PubMedCrossRefGoogle Scholar
  7. 7.
    Bigger T, Woosley R, Roden D, Hallstrom A, Echt D, Greene L, Butler L, and the CAPS investigators (1987) A placebo-controlled study of the proarrhythmic effects of class I antiarrhythmic drugs. JACC 9:245AGoogle Scholar
  8. 8.
    Bigger T, Sahar DI (1987) Clinical types of proarrhythmic response to antiarrhythmic drugs. Am J Cardiol 59: 2E-9ECrossRefGoogle Scholar
  9. 9.
    Brachmann J, Scherlag BJ, Rosenshtraukh LV, Lazzara R (1985) Brady-cardia-dependent triggered activity: relevance to drug-induced multiform ventricular tachycardia. Circulation 68:846–856CrossRefGoogle Scholar
  10. 10.
    Breithardt G, Seipel L, Haerten K, Abendroth RR, Loogen F (1979) Effektivitätskontrolle der antiarrhythmischen Therapie bei Patienten mit chronisch-re-zidivierenden ventrikulären Tachykardien mittels elektrophysiologischer Stimulationsverfahren. Z Kardiol 68:725–730PubMedGoogle Scholar
  11. 11.
    Buss J, Neuss H, Bilgin Y, Schlepper M (1985) Malignant ventricular tachyarrhythmias in association with propafenone treatment. Eur Heart J 6:424–428PubMedGoogle Scholar
  12. 12.
    Chilson DA, Heger JJ, Zipes DP, Browne K, Prystowsky EN (1985) Electrophysiologic effects and clinical efficacy of oral propafenone therapy in patients with ventricular tachycardia. J Am Coll Cardiol 5:1407–1413PubMedCrossRefGoogle Scholar
  13. 13.
    Cranefield PF, Wit AL, Hoffman BF (1973) Genesis of cardiac arrhythmias. Circulation 47:190–204PubMedCrossRefGoogle Scholar
  14. 14.
    Dangman KH, Hoffman BF (1981) In vivo and in vitro antiarrhythmic and arrhythmogenic effects of N-acetyl procainamide. J Pharmacol Exp Ther 217:851–862PubMedGoogle Scholar
  15. 15.
    Dessertenne F (1966) La tachycardie ventriculaire a deux foyers opposes variables. Arch Mal Coeur 59:263PubMedGoogle Scholar
  16. 16.
    DiBianco R, Fletcher RD, Cohen AZ, Gottdiener JS, Singh S, Katz RJ, Bates HR, Sauerbrunn B (1982) Treatment of frequent ventricular arrhythmia with en-cainide — assessment using serial ambulatory electrocardiograms, intracardiac electrophysiologic studies, treadmill exercise tests and radionuclide cine-angiographic studies. Circulation 65:1134–1144PubMedCrossRefGoogle Scholar
  17. 17.
    El-Sherif N, Scherlag BJ, Lazzara R, Hope RP (1977) Reentrant ventricular arrhythmias in the late myocardial infarction period. Mechanism of action of lidocaine. Circulation 56:395PubMedCrossRefGoogle Scholar
  18. 18.
    Goldberg D, Reiffei JA, Davis JD, Gang ES, Livelli FD Jr (1982) Electrophysiologic effects of procainamide on sinus node function in patients with and without sinus node disease. Am Heart J 103:75–82PubMedCrossRefGoogle Scholar
  19. 19.
    Hamer AW, Finerman WB, Peter T, Mandel WJ (1981) Disparaty between the clinical and electrophysiologic effects of amiodarone in the treatment of recurrent ventricular tachyarrhythmias. Am Heart J 102:992–1000PubMedCrossRefGoogle Scholar
  20. 20.
    Harrison DC, Winkle R, Sami M, Mason J (1980) Encainide: a new and potent antiarrhythmic agent. Am Heart J 100:1046–1054PubMedCrossRefGoogle Scholar
  21. 21.
    Hellestrand K, Nathan AW, Bexton RS, Camm AJ (1984) Response of an abnormal sinus node to intravenous flecainide acetate. PACE 7:436–439PubMedCrossRefGoogle Scholar
  22. 22.
    Hoffman BF, Cranefield PF (1964) The physiological basis of cardiac arrhythmias. Am J Med 37:670–684PubMedCrossRefGoogle Scholar
  23. 23.
    Hohnloser S, Zeiher A, Hust MH, Wollschläger H, Just H (1983) Flecainide-in-duced aggravation of ventricular tachycardia. Clin Cardiol 6:130–135PubMedCrossRefGoogle Scholar
  24. 24.
    Hohnloser SH, Meinertz T (1987) BID vs TID encainide for potentially lethal ventricular arrhythmias. Circulation 76 (Suppl 4): 4–368 (abstracts)Google Scholar
  25. 25.
    Hohnloser SH, Lange HW, Raeder EA, Podrid PJ, Lown B (1986) Short- and long-term therapy with tocainide for malignant ventricular tachyarrhythmias. Circulation 73:143–149PubMedCrossRefGoogle Scholar
  26. 26.
    Horowitz LN, Morganroth J (1987) Second generation antiarrhythmic agents: Have we reached the antiarrhythmic nirvana? J ACC 9:459–463Google Scholar
  27. 27.
    Horowitz LN, Greenspan AM, Rae AP, Kay HR, Spielman S (1987) Proarrhythmic responses during electrophysiologic testing. Am J Cardiol 59:45E-48ECrossRefGoogle Scholar
  28. 28.
    Kim SG, Seiden SW, Matos JA, Waspe LE, Fisher JD (1986) Discordance between ambulatory monitoring and programmed stimulation in assessing efficacy of mexiletine in patients with ventricular tachycardia. Am Heart J 112:14–19PubMedCrossRefGoogle Scholar
  29. 29.
    Kuck KH, Kunze KP, Roewer N, Bleifeld W (1984) Sotalol-induced torsade de pointes. Am Heart J 107:179–180PubMedCrossRefGoogle Scholar
  30. 30.
    Lown B, Marcus F, Levine HD (1959) Digitalis and atrial tachycardia with block. N Engl J Med 260:301–309PubMedCrossRefGoogle Scholar
  31. 31.
    Lown B, Graboys TB, Podrid PJ, Lam-pert S, Blatt CM (1986) Historic perspectives — electrical stimulation of the heart. Circulation 73 [Suppl II]: 3–10Google Scholar
  32. 32.
    Lüderitz B (1982) Typische Risiken bei der Behandlung von Herzrhythmusstörungen. Internist 23:138–143PubMedGoogle Scholar
  33. 33.
    Minardo JD, Heger JJ, Zipes DP, Miles WM, Prystowsky EN (1986) Drug associated ventricular fibrillation: analysis of clinical features and QTc prolongation. JACC 7:158AGoogle Scholar
  34. 34.
    Miura DS, Wynn J, Torres V, Laux B, Keefe D, Somberg JC (1986) Antiarrhythmic efficacy of ethmozine in patients with ventricular tachycardia as determined by programmed electrical stimulation. Am Heart J 111:661–666PubMedCrossRefGoogle Scholar
  35. 35.
    Moe GK (1975) Evidence for reentry as a mechanism of cardiac arrhythmias. Rev Physiol Biochem Pharmacol 72:56–81Google Scholar
  36. 36.
    Morganroth J, Horowitz LN (1984) Flecainide: its proarrhythmic effect and expected changes on the surface electrocardiogram. Am J Cardiol 53:89B-94BCrossRefGoogle Scholar
  37. 37.
    Morganroth J, Michelson EL, Horowitz LN, Josephson ME, Pearlman AS, Dunkman WB (1978) Limitations of routine long-term monitoring to assess ventricular ectopic frequency. Circulation 58:408–412PubMedCrossRefGoogle Scholar
  38. 38.
    Morganroth J, Anderson JL, Gentzkow GD (1986) Classification by type of ventricular arrhythmia predicts frequency of adverse cardiac events from flecainide. JACC 8:607–615PubMedCrossRefGoogle Scholar
  39. 39.
    Morganroth J, Borlan M, Chao G (1987) Application of a frequency definition of ventricular proarrhythmia. Am J Cardiol 59:97–99PubMedCrossRefGoogle Scholar
  40. 40.
    Morganroth J, Horowitz LN (1985) Incidence of proarrhythmic effects from quinidine in the outpatient treatment of benign or potentially lethal ventricular arrhythmias. Am J Cardiol 56:585–587PubMedCrossRefGoogle Scholar
  41. 41.
    Moss AJ, Schwartz PJ (1982) Delayed repolarization (QT and QTU prolongation) and malignant ventricular arrhythmias. Mod Concepts Cardiovasc Dis 51:85–90PubMedGoogle Scholar
  42. 42.
    Oravitz J, Slodki SJ (1968) Recurrent ventricular fibrillation precipitated by quinidine. Arch Intern Med 122:63CrossRefGoogle Scholar
  43. 43.
    Platia EV, Estes M, Heine DL, Griffith LS, Garan H, Ruskin JN, Reid PR (1985). Flecainide: electrophysiologic and antiarrhythmic properties in refractory ventricular tachycardia. Am J Cardiol 55:956–962PubMedCrossRefGoogle Scholar
  44. 44.
    Podrid PJ (1985) Aggravation of ventricular arrhythmia. A drug-induced complication. Drugs 29 [Suppl 4]: 33–44PubMedCrossRefGoogle Scholar
  45. 45.
    Podrid PJ, Lampert S, Graboys TB, Blatt CM, Lown B (1987) Aggravation of arrhythmia by antiarrhythmic drugs — incidence and predictors. Am J Cardiol 59:38E–44ECrossRefGoogle Scholar
  46. 46.
    Podrid PJ, Hohnloser SH, Lown B (1987) Noninvasive evaluation of inde-cainide for serious ventricular tachyarrhythmias. Am J Cardiol (in press)Google Scholar
  47. 47.
    Poser RF, Podrid PJ, Lobardi F, Lown B (1985) Aggravation of arrhythmia induced with antiarrhythmic drugs during electrophysiologic testing. Am Heart J 110:9–16PubMedCrossRefGoogle Scholar
  48. 48.
    Raeder EA, Hohnloser SH, Graboys TB, Podrid PJ, Lown B (1987) Spontaneous variability and circadian distribution of ectopic activity in patients with malignant ventricular arrhythmias. JACC (in press)Google Scholar
  49. 49.
    Reiffei JA, Bigger JT jr, Cramer M (1979) The effects of digoxin on sinus nodal function before and after vagal blockade in patients with sinus nodal dysfunction: a clue to the mechanisms of the action of digitalis on the sinus node. Am J Cardiol 43:983–989CrossRefGoogle Scholar
  50. 50.
    Roden DM, Hoffman BF (1985) Action potential prolongation and induction of abnormal automaticity by low quinidine concentrations in canine Purkinje fibers: relationship to potassium and cycle length. Circ Res 56:857–867PubMedCrossRefGoogle Scholar
  51. 51.
    Roden DM, Woosley RL, Primm RK (1986) Incidence and clinical features of the quinidine-associated long QT syndrome: implications for patient care. Am Heart J 111:1088–1093PubMedCrossRefGoogle Scholar
  52. 52.
    Rosen MR, Wit AL (1987) Arrhythmo-genic actions of antiarrhythmic drugs. Am J Cardiol 59:10E–18ECrossRefGoogle Scholar
  53. 53.
    Ruskin JN, McGovern B, Garan H, DiMarco JP, Kelly E (1983) Antiarrhythmic drugs: A possible cause of out-of-hospital cardiac arrest. N Engl J Med 309:1302–1306PubMedCrossRefGoogle Scholar
  54. 54.
    Selzer A, Wray HW (1964) Quinidine syncope. Circulation 30:17PubMedCrossRefGoogle Scholar
  55. 55.
    Slater W, Podrid P, Lampert S, Lown B (1986) Are there clinical predictors for arrhythmia aggravation? JACC 7:158AGoogle Scholar
  56. 56.
    Stavens CS, McGovern B, Garan H, Ruskin JM (1985) Aggravation of electrically provoked ventricular tachycardia during treatment with propafenone. Am Heart J 110:24–29PubMedCrossRefGoogle Scholar
  57. 57.
    Steinbeck G, Lüderitz B (1977) Störungen der Sinusknotenfunktion. Diagnostik und klinische Bedeutung. Dtsch Med Wochenschr 102:35PubMedCrossRefGoogle Scholar
  58. 58.
    Talajic M, Brugada P, Della Bella P, Du-gernier T, Lemery R, Wellens HJJ (1987) Prognostic significance of proarrhythmic effects during electrophysiologic testing. JACC 9:98AGoogle Scholar
  59. 59.
    Torres V, Flowers D, Somberg JC (1985) The arrhythmogenicity of antiarrhythmic agents. Am Heart J 109:1090–1097PubMedCrossRefGoogle Scholar
  60. 60.
    Weirich J, Antoni H (1986) Vulnerability of the heart to ventricular fibrillation: basic mechanisms. In: Rupp H (Hrsg) The regulation of the heart function. Basic concepts and clinical applications. Thieme, New YorkGoogle Scholar
  61. 61.
    Wellens HJ, Schuielnburg RM, Durrer D (1972) Electrical stimulation of the heart in patients with ventricular tachycardia. Circulation 46:216–226PubMedCrossRefGoogle Scholar
  62. 62.
    Winkle RA, Mason JW, Griffen JC, Ross D (1981) Malignant ventricular tachycardia associated with the use of encainide. Am Heart J 102:857–864PubMedCrossRefGoogle Scholar
  63. 63.
    Woosley RL, Roden DM (1987) Pharmacologic causes of arrhythmogenic actions of antiarrhythmic drugs. Am J Cardiol 59:19E–25ECrossRefGoogle Scholar
  64. 64.
    Vaughan Williams EM (1970) Classification of antiarrhythmic drugs. In: Sand-hoe E, Astral AB (Hrsg) Symposium on cardiac arrhythmias. Södertälje, Schweden, pp 449–472Google Scholar
  65. 65.
    Velebit V, Podrid P, Lown B, Cohen BH, Graboys TB (1982) Aggravation and provocation of ventricular arrhythmias by antiarrhythmic drugs. Circulation 65:886–894PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1988

Authors and Affiliations

  • S. H. Hohnloser
    • 1
  • T. Meinertz
    • 1
  • M. Zehender
    • 1
  • A. Geibel
    • 1
  • H. Just
    • 1
  1. 1.Abteilung KardiologieMedizinische Universitätsklinik IIIFreiburg i. BrDeutschland

Personalised recommendations